ORAMED PHARMACEUTICALS INC. (ORMP): M&A transaction — Oramed Pharmaceuticals completes sale of subsidiary Oratech to Lifeward and purchases $9M convertible notes

ORAMED PHARMACEUTICALS INC.

Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.
Oramed purchased $9,000,000 aggregate principal of Lifeward senior secured convertible notes with initial conversion price of $5.40 per share.
Oramed also received purchase agreement warrants to buy up to 1,666,666 Lifeward ordinary shares at $5.40 per share.
Oramed is entitled to ongoing revenue sharing payments equal to 4% of net revenue from Lifeward's ReWalk exoskeleton products.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ORAMED PHARMACEUTICALS INC. completed a disposition involving Lifeward Ltd. for Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward, and pre-funded warrants to purchase the number of Lifeward Ord (closed 2026-03-25).

Action: disposition
Counterparty: Lifeward Ltd.
Consideration: Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward, and pre-funded warrants to purchase the number of Lifeward Ord
Closing: 2026-03-25

Exact text from the filing

On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.

View on SEC.gov

Browse all m&a transactions →

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-037474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.